(May 21 07:33) Reuters.com Business
Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients.
You can find the original article
here